Spironolactone v placebo for severe congestive heart failure (CHF)â€
| Outcomes at mean 24 mo | Spironolactone | Placebo | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| †Abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article. | ||||
| All-cause mortality | 35% | 46% | 25% (15 to 33) | 9 (7 to 16) |
| Cardiac mortality | 28% | 37% | 26% (15 to 36) | 11 (7 to 19) |
| CHF mortality | 16% | 23% | 31% (16 to 44) | 15 (10 to 31) |
| Hospitalisation for cardiac causes | 32% | 40% | 21% (10 to 31) | 13 (8 to 27) |